Clinical, laboratory, and neuroimaging characteristics of fatigue in HIV-infected individuals

Keyphrases

• HIV Patients 100%
• Clinical Neuroimaging 100%
• Clinical Laboratory 100%
• Magnetic Resonance Spectroscopy 100%
• Brain Metabolites 100%
• Neuropsychological Tests 66%
• Basal Ganglia 66%
• CD4 Count 66%
• Cellular Energy 66%
• Brain Regions 33%
• Demographic Characteristics 33%
• Confidence Interval 33%
• Depressive Symptoms 33%
• Clinical Characteristics 33%
• Brain Activity 33%
• Stroop 33%
• Randomized Placebo-controlled Trial 33%
• Longitudinal Assessment 33%
• Glia 33%
• Center for Epidemiologic Studies Depression Scale (CES-D) 33%
• MRNA Abundance 33%
• Disease Status 33%
• Depressed Mood 33%
• Transdermal 33%
• HIV RNA 33%
• Striatal 33%
• HIV-associated Neurocognitive Disorders 33%
• Longitudinal Data 33%
• Cognitive Tests 33%
• Karnofsky Performance Status 33%
• Frontal Lobe 33%
• Cell Markers 33%
• MR Spectroscopic Imaging (MRSI) 33%
• Common Symptoms 33%
• In Vivo Methods 33%
• Functional Performance 33%
• Baseline Evaluation 33%
• Selegiline 33%
• Energy Levels 33%
• Brain Magnetic Resonance 33%
• Fatigue Severity Scale 33%
• Dysmetabolism 33%
• Cortical Circuitry 33%
• Fatigue Test 33%

Neuroscience

• Human Immunodeficiency Virus 100%
• Nuclear Magnetic Resonance Spectroscopy 80%
• Neuropsychological Test 40%
• Basal Ganglia 40%
• CD4 40%
• Cell Energy 40%
• Blood Plasma 40%
• Cognitive Disorders 20%
• In Vivo 20%
• Placebo 20%
• Glia 20%
• Frontal Lobe 20%
• Cognitive Tests 20%
• Selegiline 20%
• Electroencephalogram 20%
• Brain Region 20%